Canton Hathaway’s DexCom DXCM Stock Holding History

Canton Hathaway’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,392	Closed	-$41K	–	256
2019 Q1	$41K	Buy	+1,392	New	+$48.9K	0.02%	129

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Canton Hathaway's DXCM Position: Q2 2019 in Review

Canton Hathaway sold out of DexCom (DXCM) in Q2 2019, closing a stake of 1,392 shares — an estimated $41K sold.

Canton Hathaway first reported a position in DXCM in Q1 2019 and held it in 1 quarter. The position peaked at $41K in Q1 2019. 418 funds tracked by Wall St. Rank hold DXCM as of Q2 2019.

Canton Hathaway reported no remaining DexCom position as of Q2 2019 after selling out during the quarter.
Canton Hathaway sold 1,392 DexCom shares in Q2 2019, an estimated $41K.
Canton Hathaway first reported a position in DexCom in Q1 2019 and held it in 1 quarter.
Canton Hathaway's DexCom position peaked at $41K in Q1 2019.
418 funds tracked by Wall St. Rank held DexCom as of Q2 2019.

Based on Canton Hathaway's 13F filing for Q2 2019, filed 15 Jul 2019.